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There are unique stressors in the spaceflight environment. Exposure to such stressors
may be associated with adverse effects on astronauts’ health, including increased cancer
and cardiovascular disease risks. Small extracellular vesicles (sEVs, i.e., exosomes)
play a vital role in intercellular communication and regulate various biological processes
contributing to their role in disease pathogenesis. To assess whether spaceflight alters
sEVs transcriptome profile, sEVs were isolated from the blood plasma of 3 astronauts
at two different time points: 10 days before launch (L-10) and 3 days after return
(R+3) from the Shuttle mission. AC16 cells (human cardiomyocyte cell line) were treated
with L-10 and R+3 astronauts-derived exosomes for 24 h. Total RNA was isolated
and analyzed for gene expression profiling using Affymetrix microarrays. Enrichment
analysis was performed using Enrichr. Transcription factor (TF) enrichment analysis
using the ENCODE/ChEA Consensus TF database identified gene sets related to the
polycomb repressive complex 2 (PRC2) and Vitamin D receptor (VDR) in AC16 cells
treated with R+3 compared to cells treated with L-10 astronauts-derived exosomes.
Further analysis of the histone modifications using datasets from the Roadmap
Epigenomics Project confirmed enrichment in gene sets related to the H3K27me3
repressive mark. Interestingly, analysis of previously published H3K27me3–chromatin
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immunoprecipitation sequencing (ChIP-Seq) ENCODE datasets showed enrichment
of H3K27me3 in the VDR promoter. Collectively, our results suggest that astronautderived sEVs may epigenetically repress the expression of the VDR in human adult
cardiomyocytes by promoting the activation of the PRC2 complex and H3K27me3 levels.
Keywords: astronauts, spaceflight, EZH2, vitamin D receptor, small extracellular vesicles, epigenetic

INTRODUCTION

intracellular communication can be attributed to their cargo
that contains various biomolecules like RNA, DNA, proteins,
and other metabolites (12, 13). Several studies have implicated
exosomes in various diseases and processes, including (1)
immune process (i.e., cytokine production, antigen presentation,
and NK-cell activation) (14–18), (2) CVD (atherosclerosis,
myocardial ischemia and reperfusion injury, heart failure, and
cardiomyopathy) (19–24), and (3) cancer (22, 25, 26), etc.
Considering their role in disease pathogenesis, we hypothesize
that exosomes may mediate the harmful effects of spaceflightassociated stressors by altering the gene expression profile of
various cells throughout the body. In this study, we found
that astronaut-derived exosomes increased inflammation and
oxidative stress in the AC16 human cardiomyocyte cell line.
Interestingly, we uncovered enrichment in gene sets associated
with SUZ12, vitamin D receptor (VDR), and H3K27me3 in AC16
cells treated with exosomes isolated at three days post landing
(ExoR+3) compared to those treated with exosomes isolated 10
days before the flight (ExoL-10). Further, analysis of the VDR
promoter revealed that ExoR+3 represses VDR expression by
promoting H3K27me3 enrichment in the VDR promoter in an
EZH2-dependent manner. Taken together, our results suggest
that VDR agonists may be used to reduce exosome-mediated
oxidative stress and inflammation in astronauts.

With the rapid expansion of the commercial aerospace industry
and future deep-space exploration to the Moon and Mars, space
travel is now entering a new area. Thus, it is critical to understand
the short- and long-term health risks associated with the space
environment during low Earth orbit (LEO) space missions,
such as those onboard the International Space Station (ISS), to
inform countermeasure and mitigation plans for future deepspace missions. Thus far, only 12 astronauts from the Apollo
missions have traveled beyond the Earth’s protective geomagnetic
Van Allen radiation belt, which shields the Earth from galactic
cosmic rays (1–3). Notably, previous studies showed that Apollo
astronauts exhibit higher morbidity/mortality rates associated
with cardiovascular disease (CVD) compared to non-flight
astronauts and astronauts who flew only LEO missions (4).
Considering observed health risks may be modified by several
spaceflight factors (i.e., duration, distance from Earth, etc.),
further studies are needed to elucidate underlying molecular
mechanisms driving cellular dysfunction that may lead to disease
to inform mitigation and countermeasure plans.
Accumulating evidence shows that physical and psychological
factors associated with spaceflight (isolation, confinement,
acceleration at launch, sleep deprivation, microgravity, and space
radiation) may dysregulate astronauts’ genetic, transcriptional,
and metabolic profiles (5). For example, transcriptional profiling
of whole blood collected from six astronauts who flew relatively
short (up to 14 days) Shuttle missions showed genes involved
in DNA repair (XRCC1, HHR23A), oxidative stress (GPX1),
and chaperones (HSP27, HSP90AB1) to be downregulated
post-spaceflight and proto-oncogene C-FOS to be upregulated
(6). In addition, our group has demonstrated that circulating
levels of cell-free mitochondrial DNA (cf-mtDNA) are elevated
after relatively short Shuttle missions and are associated with
elevated transcripts of DNA damage, oxidative stress, and
inflammatory markers in peripheral blood mononuclear cells
(PBMCs) (7). Furthermore, NASA’s Twin study found that
year-long LEO spaceflight was associated with altered telomere
dynamics inflight, differential expression of genes related to
DNA repair, immune function, oxidative stress, apoptosis, and
mitochondrial respiration in PBMCs, and altered genome-wide
DNA methylation in CD4 and CD8 cells (8). Thus, such
genomic, epigenomic, or transcriptional alterations may provide
metrics for monitoring astronauts’ health before, during, and
after spaceflight.
Exosomes are small extracellular vesicles (sEVs) measuring
30–140 nm with a notable role in autocrine and paracrine
signaling and thus mediate essential biological functions involved
in cell physiology and human diseases (9–11). Their roles in
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MATERIALS AND METHODS
Astronaut Samples
Blood was sampled 10 days before launch (L-10) and 3 days after
return (R+3) from 3 astronauts (Sample ID: D12, D13, and D14)
who flew short (up to 14 days) Shuttle missions between 1998
and 2001. Information regarding de-identified blood samples and
the binned age of the crew members at launch are provided in
Table 1. All samples were stored at −80◦ C until use.

Thrombin Plasma Preparation for Exosome
Precipitation
Exosomes were isolated from blood plasma samples of 3
astronauts (Sample ID: D12, D13, and D14) at L-10 and R+3

TABLE 1 | Information regarding de-identified blood samples from 3 astronauts,
including the binned age of the crew members at launch and sample ID number.
Sample ID #

2

Binned age at launch in years

D12

≥50

D13

<40

D14

<40
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(Supplemental Figure 1). CellROX R Green Reagent is a
novel fluorogenic probe for measuring oxidative stress in live
cells with absorption/emission maxima of ∼485/520 nm. Briefly,
AC16 cells were incubated with CellROX R Green Reagent at a
final concentration of 5 µM for 30 min at 37◦ C. Then, the cells
were washed three times with PBS and analyzed by traditional
fluorescence microscopy and microplate-based fluorimetry.

using the ExoQuick Plasma prep and exosome precipitation kit
(Cat # EXOQ5TM, System Biosciences, CA, USA), as previously
described (7). Briefly, thrombin was added to the plasma and
incubated for 5 min at room temperature. Next, samples were
centrifuged at 10,000 rpm for 5 min, and the supernatant was
incubated with the exosome precipitation solution for 30 min at
4◦ C. Samples were centrifuged for 30 min at 1,500 × g at 4◦ C,
and the pellet was dissolved in 100 µl of sterile 1× PBS.

Western Blot

Exosome Uptake

AC16 cells were collected and resuspended in RIPA lysis buffer
(ThermoFisher) containing a Protease and Phosphatase Inhibitor
Cocktail (Roche) and analyzed as previously described (27).
Briefly, samples were centrifuged, and the supernatants were
collected. Protein concentration was determined by BCA assay
(Sigma-Aldrich). Fifty microgram total protein was loaded on
a 4–20% mini-protean TGX precast protein gel and transferred
to a polyvinylidene difluoride membrane. The membrane was
blocked with 5% skim milk and probed with the primary
antibodies diluted at 1/1,000 (EZH2, Cell signaling # #5246S;
GAPDH, Invitrogen, #AM4300; H3K27me3, Cell signaling,
#9733S, Histone H3, Cell Signaling, #9715S) overnight at
4◦ C followed by corresponding secondary HRP-conjugated
antibodies (Cell signaling). The blots were developed using
the SuperSignal West Dura Reagent (Thermo Scientific) and
visualized using a BioRad imager.

Isolated sEVs were labeled using an SBI’s ExoGlow-MembraneTM
EV Labeling kit (Cat # EXOGM600A-1, System Biosciences, CA,
USA) according to the manufacturer’s protocol.

Cell Culture and Treatment
AC16 human cardiomyocyte cell line was cultured in DMEM/F12
containing 2 mM L-Glutamine, 10% exosomes-free FBS, and 1%
Penicillin/Streptomycin Solution. Based on our exosome uptake
data, in vitro assays were performed using ExoL-10 and ExoR+3
isolated (108 particles/mL) from Astronaut D14. After 24 h (postsEV treatment), cells were co-treated with either GSK126 (1 µM,
SelleckChem) for an additional 48 h, a potent EZH2 inhibitor, or
paricalcitol (10 nM, SelleckChem), a synthetic vitamin D analog,
for an additional 24 h (Supplementary Figure 1).

RNA Isolation
For Affymetrix microarrays, total RNA was extracted from AC16
cells treated with astronaut-derived ExoL-10 and ExoR+3 (108
particles/mL) for 24 h using the RNeasy Mini Kit (Qiagen),
according to the manufacturer’s protocol. High-quality RNA
was isolated using RNeasy Mini spin columns and eluted using
molecular-grade water (RNAse/DNAse free).

ChIP-qPCR
We performed ChIP-qPCR to measure the level of H3K27me3
in the VDR promoter in AC16 pre-treated for 24 h with ExoL-10
or ExoR+3 (108 particles/mL) before co-treatment with GSK126
for 48 h (Supplementary Figure 1). At 72 h post-initial sEV
treatment, AC16 cells were washed twice with cold PBS after
removing the culture media, and chromatin was cross-linked
immediately by adding 1% formaldehyde (Sigma-Aldrich,
F8775) to the cell culture media and incubated for 10 min
at room temperature. Next, cells were incubated with 1×
glycine for 10 min to quench excessive formaldehyde and rinsed
twice with cold PBS. Cells were collected using a sterile cell
scraper. Cells were resuspended and washed by centrifugation
in sterile ice-cold PBS containing 1× Halt protease inhibitor
cocktail (ThermoFisher). After centrifugation, the cell pellet was
resuspended using cell lysis buffer containing protease inhibitor
cocktail, followed by the addition of Nuclear Lysis Buffer, and
ChIP assay was carried out as recommended by the manufacturer
using EZ-Magna ChIPTM Chromatin Immunoprecipitation Kit
(Millipore, 17-10086). Samples were incubated with 5 ug of
ChIP-grade antibody against H3K27me3 (Abcam, ab6002)
overnight at 4◦ C using a rotating platform. Non-specific
IgG was used as a control. After IP, the chromatin-antibody
conjugates were washed sequentially with low salt, high salt,
lithium chloride, and TE buffer. Then, samples were incubated
with Proteinase K at 62◦ C for 2 h with shaking (1,400 RPM),
followed by 95◦ C for 10 min. A ≈175 bp region within the
VDR promoter was amplified using the following primers:
forward—GGTAAACTTGGCTACTGAGGTC and reverse—
GGAAACAAATACTTCTTGTTGCCC. Relative H3K27me3
enrichment in the VDR promoter sequence in input, ChIP, and

Affymetrix Microarrays and Data Analysis
All samples first underwent quality control assessment to ensure
successful library preparation. RNA sample quality was assessed
by NanoDrop and Agilent 2100 BioAnalyzer. Samples with RNA
integrity number (RIN) above 7, OD260/280: 2, and OD260/230
≥ 2 were used. In addition, RNA degradation and contamination
were monitored on 1% agarose gels before Affymetrix
microarrays. DEGs were analyzed using the integrative
web-based gene list enrichment analysis tool ENRICHR
(http://amp.pharm.mssm.edu/Enrichr/, accessed 09/2020),
followed by transcription factor (TF) enrichment analysis
using the Encyclopedia of DNA Elements (ENCODE)/ChIP-X
Enrichment Analysis (CheA) database. In addition, the NIH
Roadmap Epigenomics Consortium that integrated epigenomic
maps were generated from ChIP-seq datasets obtained using 127
human tissues and primary cells with antibodies targeting over
30 different histone modification marks.

Oxidative Stress
AC16 cells were treated either with ExoL-10 or ExoR+3
(108 particles/mL) for 24 h and then stained with CellROXTM
Green Reagent for oxidative stress detection at the following
time intervals: without cotreatment (sEVs alone) at 24 h
post-sEV treatment, co-treatment with GSK126 (72 h postsEVs), co-treatment with Paricalcitol (48 h post-sEVs)
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exosomes from the peripheral blood of 3 astronauts at L-10
(ExoL-10) and R+3 (ExoR+3). Exosomes were characterized
by nanoparticle tracking analysis for size distribution and
concentration and analyzed using an exosome-specific antibody
array. Nanosight and Exo-Check Antibody Array data for the
exosomes used in this study were recently published by Bisserier
et al. (7). Next, AC16 cells were treated with L-10 and R+3
astronaut-derived exosomes that were labeled with Exo-Glow
(ExoL-10, ExoR+3) for 24 h. Our results confirmed exosome
uptake by AC16 cells (Figure 1A).
Considering the role of exosomes in various biological
processes, we further assessed the effects of astronaut-derived
exosomes on oxidative stress and inflammation. Our results show
that both ExoL-10 and ExoR+3 increased oxidative stress 24 h
post-treatment compared to untreated AC16 cells, though the
degree of increase was slightly more pronounced in ExoR+3
treated cells compared to ExoL-10 treated cells (Figure 1B).
We also analyzed the transcript levels of various inflammatory
markers (TNF-α, IL-6, IL1-α, IL1-β), which revealed a significant
increase in gene expression levels of all inflammatory markers
in AC16 treated ExoR+3 for 24 h when compared to control
untreated samples (Figure 1C).

IgG samples was quantified using the Fast SYBR Green qPCR
system (Applied Biosystems). DNA isolated from negative IgG
control IP samples showed undetermined to negligible DNA
amplification for VDR promoter, ensuring antibody specificity.
Enrichment of DNA sequence (VDR promoter) in IP samples
was then calculated as a percentage of input (% input) within the
sample. Fold change between groups was expressed as relative to
control samples.

Total RNA Isolation, cDNA Preparation, and
Quantitative RT-PCR Analysis
For the mRNA expression analyses, total RNA was extracted
using TRIzolTM (Invitrogen) and purified using RNeasy
mini columns (Qiagen). According to the manufacturer’s
instructions, the cDNA synthesis kit (Applied Biosystems,
Foster City, CA) was used to generate cDNA. Quantitative
RT-PCR was performed using the PerfeCTa SYBRTM Green
FastMix kit (Quantabio) according to the manufacturer’s
instructions. Samples were analyzed using the ABI Prism
7500 Real-Time PCR System (Applied Biosystems, Foster
City, CA). Fold changes in gene expression were determined
using the relative comparison method with normalization to
GAPDH as an internal control. The primer sequences are
provided Table 2:

Enrichment Analysis of AC16 Treated With
Astronaut-Derived Plasma Exosomes

Statistical Analysis

We treated AC16 cells with ExoL-10 and ExoR+3 isolated from
3 astronauts, and total RNA was isolated and analyzed for gene
expression profiling using Affymetrix microarrays (Figure 2A).
Computational analysis of microarray datasets revealed 186
differentially expressed genes (DEGs), 65 down- and 121 upregulated, in the AC16 treated with ExoR+3 compared to AC16
treated with ExoL-10 (Figure 2B). Gene list enrichment analysis
using ENRICHR and transcription factor (TF) enrichment
analysis using ENCODE/ChEA database identified SMAD4,
SUZ12, IRF8, GATA2, and VDR amongst the most enriched
TFs (Figure 2C, upper panel). Polycomb repressive complex
2 (PRC2), formed by SUZ12, EZH2 (Enhancer Of Zeste 2
Polycomb Repressive Complex 2 Subunit), and EDD subunits,
plays a key role in the coordination of Polycomb mediated gene
silencing, chromatin compaction, and methylation of histone
H3 at lysine 27 (H3K27me3) (28). SUZ12 plays an essential
role in maintaining the integrity of PRC2 and the stability of

Results are presented as mean ± standard error of the mean. Data
were analyzed using an unpaired t-test for comparisons between
means 1-way analysis of variance with the Tukey correction
for comparisons between >2 groups. Statistical analysis was
performed using GraphPad Prism software (GraphPad Software,
Inc., La Jolla, CA). Differences were considered significant at P
< 0.05. Corresponding symbols in the figures are ∗ for P < 0.05,
∗∗ for P < 0.01, ∗∗∗ for P < 0.001, and ns for not significant.

RESULTS
Astronaut-Derived sEVs Promote Oxidative
Stress and Inflammation Markers in AC16
Cells
To better understand the role of sEVs and their implication
in spaceflight-associated adverse health effects, we isolated
TABLE 2 | Primer sequences for RT-qPCR analysis.
Application
RT-qPCR

Gene symbol

Species

EZH2

Human

′

′

Forward primer (5 -3 )

′

′

Reverse primer (5 -3 )

TCCCGCTGAGGATGTGGATA

GGGCACGAACTGTCACAAGG

GAPDH

CGACCACTTTGTCAAGCTCA

AGGGGAGATTCAGTGTGGTG

IL1A

AAGAAGACAGTTCCTCCATTGATCA

CCTTGAAGGTAAGCTTGGATGTTTT

IL1B

ATGATGGCTTATTACAGTGGCAATG

ATCTTCCTCAGCTTGTCCATGG

IL6

ACAAGAGTAACATGTGTGAAAGCAG

ACTCTCAAATCTGTTCTGGAGGTAC

IL8

TTGCCAAGGAGTGCTAAAGAACTTA

AGCTCTCTTCCATCAGAAAGCTTTA

SUZ12

TGCATTGCCCTTGGTGTACT

GCAAATCCAGGTTGGCGATG

TNF

CTTGTTCCTCAGCCTCTTCTCCTTC

GGGTTCGAGAAGATGATCTGACTG

VDR

CTGCATCGTCTCCCCAGATC

GGTCGGCTAGCTTCTGGATC
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FIGURE 1 | Astronauts-derived exosomes induce transcriptional changes in AC16. (A) Exosomes from L-10 and R+3 (ExoL-10, ExoR+3) were isolated from 3
astronauts (Sample ID: D12, D13, and D14) and labeled using an SBI’s ExoGlow-MembraneTM EV Labeling kit. Next, labeled sEV were used to treat AC16 cells for
24 h. Representative pictures of AC16 cells are shown (left panel). Scale bars, 100 µm. Respective quantification is provided, right panel, n = 3. (B) Oxidative stress
levels were measured using CellROXTM Green Reagent in untreated cells and AC16 cells treated for 24 h with ExoL-10 and ExoR+3 isolated from astronaut D14, n =
4. Scale bars, 50 µm. Cells were visualized by fluorescence microscopy and quantified using a fluorescent spectrophotometer. (C) Transcript levels of inflammation
markers (TNF-α, IL-6, IL-1 α, and IL-1β) were measured by qPCR in the indicated conditions after 24 h, n = 4. Statistical significance was determined by one-way
ANOVA followed by Tukey post-test. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant.

VDR expression, compared to ExoL-10 treated AC16
(Figure 2D). Interestingly, SUZ12 and EZH2 were also
upregulated in ExoL-10-treated AC16 compared to
untreated cells.

EZH2 and thus maintains a critical role in modifying the histone
methyltransferase activity of the complex. Specifically, SUZ12 is
responsible for catalyzing H3K27me3.
Thus, we used a gene-set library associated with
histone modifications extracted from the Roadmap
Epigenomics Project (Figure 2C, lower panel) for
our 186 DEGs. We found significant enrichment in
the repressive histone methylation mark H3K27me3
(Figure 2C, lower panel). qRT-PCR validation confirmed
that ExoR+3 astronaut-derived exosomes significantly
increased SUZ12 and EZH2 expression while repressing
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Enrichment of H3K27me3 in VDR Promoter
and Its Functional Consequence
To better define the contribution of PRC2 to the epigenetic
regulation of VDR expression after spaceflight, we treated
AC16 cells with ExoL-10 and ExoR+3 derived from astronaut
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FIGURE 2 | Identification of epigenetic and transcriptional changes in AC16 treated with astronauts-derived exosomes by Affymetrix microarrays. (A) Schematic
representation of the experimental design. Blood was drawn 10 days before launch (L-10) and 3 days after return (R+3) from 3 different astronauts. The exosomes
from L-10 and R+3 (ExoL-10, ExoR+3) were isolated from 3 different astronauts and then used to treat AC16 cells for 24 h. RNA from AC16 cells was isolated and
analyzed using Affymetrix microarrays. Created with BioRender.com. (B) Volcano plots showing Log2-fold changes for the differentially expressed genes (DEG) and
the statistical significance of each gene calculated after DEG analysis. Red points indicate significantly down-regulated genes; green points indicate up-regulated
genes. (C) Gene list enrichment analysis was conducted using ENRICHR. Upper panel: transcription factor enrichment analysis (TFEA) using ENCODE/ChEA
database. Lower panel: Epigenomic analysis using a gene-set library from the Roadmap Epigenomics Project. (D) qRT-PCR was performed on untreated cells and
AC16 cells treated with ExoL-10- and ExoR+3 isolated from Astronaut D14 for 24 h, n = 3. Statistical significance was determined by one-way ANOVA followed by
Tukey post-test. *P < 0.05, **P < 0.01, ***P < 0.001.

suggesting that astronaut-derived exosomes may repress
VDR expression by promoting H3K27me3 abundance within
the promoter region. Furthermore, assessment of enrichment
of H3K27me3 in the VDR by ChIP-qPCR showed that ExoR+3
significantly increased H3K27me3 enrichment within the
VDR promoter region in AC16 compared to untreated cells
or ExoL-10-treated cells (Figure 3E). Moreover, we used
GSK126 to examine the impact of pharmacologic inhibition
of PRC2-EZH2 activity on H3K27me3 abundance in the
VDR promoter. Our results demonstrated that impairment
of the PRC2-EZH2 activity significantly decreased EZH2induced H3K27me3 enrichment in the VDR promoter
(Figure 3E) and was associated with the restoration of VDR
expression (Figure 3F). Collectively, our data suggested that
astronaut-derived exosomes may repress VDR expression in an
H3K27me3-dependent manner.

D14 for 24 h and analyzed by immunoblotting for EZH2
and H3K27me3 levels. Our results demonstrated that both
astronaut-derived ExoL-10 and ExoR+3 treatment potentiated
EZH2 expression and increased global levels of H3K27me3
in AC16 cells (Figure 3A). Next, we used GSK126, a potent
and highly selective EZH2 methyltransferase inhibitor, to
examine the impact of pharmacologic inhibition of PRC2EZH2 activity on oxidative stress and inflammation induced
by astronaut-derived exosomes. Interestingly, we found that
after 48 h of GK126 treatment, EZH2 inhibition alleviated
oxidative stress and the expression of pro-inflammatory markers
in cells treated in combination with ExoR+3 (Figures 3B,C).
Finally, we also analyzed previously published H3K27me3–
ChIP ENCODE datasets to understand the role of PRC2 on
epigenetic regulation of VDR expression. We found enrichment
in H3K27me3 within the VDR promoter (Figure 3D),
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FIGURE 3 | Epigenetic regulation of VDR via H3K27me3 in AC16 treated with astronauts-derived exosomes. (A) AC16 cells were treated with ExoL-10 or ExoR+3
(108 particles/mL) for 24 h and analyzed by immunoblotting for EZH2, H3K27me3. Histone H3 and GAPDH were used as loading controls. A representative
immunoblot is shown. (B) Oxidative stress levels were measured using CellROXTM Green Reagent in untreated cells and AC16 cells pretreated for 24 h with ExoL-10
and ExoR+3-isolated from astronaut D14 alone or combined with GSK126 (1 µM, treatment at 24 h post-sEVs) for an additional 48 h, n = 4. Cells were visualized by
fluorescence microscopy and quantified using a fluorescent spectrophotometer. Scale bars, 50 µm. (C) Transcript levels of inflammation markers (TNF-α, IL-6, IL-1 α,
and IL-1β) were measured by qPCR in AC16 pretreated for 24 h with ExoL-10 and ExoR+3 alone or cotreated with GSK126 (1 µM) for an additional 48 h, n = 3. (D)
(Continued)
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FIGURE 3 | VDR promoter was analyzed using H327me3-ChIP ENCODE datasets. (E) H3K27me3 abundance in the VDR promoter was measured by ChIP-qPCR in
AC16 cells pretreated for 24 h with ExoL-10 and ExoR+3 alone or in combination with a specific inhibitor against EZH2 (GSK126; 1 µM) after 48 h. (F) VDR mRNA
levels were measured by qPCR in AC16 treated with ExoL-10 and ExoR+3 alone or combined with GSK126 (1 µM) 72 h after initial exosome treatment. Statistical
significance was determined by one-way ANOVA followed by Tukey post-test. *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant.

Paricalcitol Inhibits the Expression of
Oxidative Stress and Inflammation
Markers in AC16 Treated With
Astronaut-Derived Exosomes

to early phase clinical trials in the context of various lymphomas
and advanced solid tumors (NCT01897571), mesothelioma
(NCT02860286), sarcoma (NCT02601950). Importantly,
our report emphasizes the importance of characterizing the
exosomal protein and RNA cargo to understand better how
astronaut-derived exosomes affect histone modifications, gene
expression, and biological responses in recipient cells. Our
group has previously purified exosomal RNA and analyzed the
transcriptome changes associated with spaceflights by small
RNA-sequencing (sRNAseq). Our analysis of the sRNASeq
datasets suggested that miR-214 (FDR 0.05; Log2fold−2.3) and
miR-128 (FDR 0.1; Log2 fold−1.5), whose expression negatively
correlates with EZH2 and SUZ12, respectively, were significantly
downregulated 3 days post-flight (R+3) compared to baseline
(L-10) (Supplementary Table 1). Downregulation of these
miRs may increase the expression of both PRC2 components,
thereby promoting the activation of the PRC2 complex and
H3K27me3 levels in AC16 cells treated with exosomes isolated
from astronauts at R+3. Other known miRNA (miR-144, miR625, miR-31, miR-200b) and lncRNA (Meg3, SNHG6) targets of
EZH2 and SUZ12 were detected, though there was no significant
change in expression of these non-coding RNA post-flight.
Therefore, further studies validating the role of these miR in
counteracting EZH2-mediated epigenetic regulation may be of
interest. We also noted that ExoL-10 and ExoR+3 treatments
induced a different degree of response with regards to oxidative
stress and inflammation in a time-specific manner. Indeed,
increasing evidence indicates that epigenetic regulation is a
dynamic and complex molecular mechanism that can regulate
chromatin structure and accessibility within a few minutes
(48, 49). Indeed, histone modifications, such as methylation
and/or acetylation, are a highly specific epigenetic mark that is
controlled by different regulatory processes in a time-sensitive
window with gene-specific transcriptional outcomes (50).
Because epigenetic modifications determine which genes are
upregulated on a transient timescale upon cellular activation
but also control stable gene expression on a timescale that
extends beyond the initial stimuli (51), time-specific differences
in response to sEVs treatment may suggest that oxidative stress
and inflammation may be epigenetically regulated in AC16 cells.
In addition, we also observed that the longer the treatment
course with sEVs, the stronger the induction of oxidative stress
and inflammatory response. For example, we also noted that
differences in response between ExoL-10 and ExoR+3 treatment
are more pronounced at 72 h compared to 24 or 48 h. Further
investigation would be needed to increase the sample size and
draw more robust conclusions to fully evaluate the therapeutic
potential of this pathway.
Our study showed that astronaut-derived exosomes may
repress VDR expression by promoting EZH2-mediated
H3K27me3 in AC16 cells. Growing evidence from several

Previous studies suggested that vitamin D deficiency or defective
VDR may be detrimental to cardiovascular health and other
diseases, such as cancer, infectious and autoimmune diseases. To
evaluate the therapeutic potential of vitamin D supplementation
in astronauts, we used a synthetic vitamin D analog paricalcitol
to selectively activate vitamin D responsive pathways in
AC16 cells pretreated with ExoL-10 and ExoR+3 for 24 h.
Paricalcitol treatment significantly inhibited oxidative stress
(Figure 4A), and inflammation (Figure 4B) at 48 h in AC16
treated with ExoR+3. Notably, our study suggests that vitamin
D supplementation in astronauts may represent a strategic and
efficient approach for mitigating health risks associated with
space travel.

DISCUSSION
Spaceflight and its various stressors are associated with various
adverse health effects for astronauts who flew short or longduration LEO missions. These risks will be further modified
during deep space exploration missions to the Moon and
Mars, increasing the need to understand the mechanisms
behind cell/tissue and an organ perturbation to inform future
countermeasures and mitigation plans. Collectively, this pilot
study suggests that relatively short LEO spaceflight may be
associated with epigenetic silencing of VDR function, and
supplementation with vitamin D may represent a strategic
and efficient approach for mitigating space flight-associated
health risks.
Considering PRC2’s role in epigenetic regulation of
downstream gene expression, its catalytic subunit EZH2 has
emerged as a therapeutic target of interest. EZH2 overexpression
and gain-of-function mutations are associated with aberrantly
high H3K27 trimethylation levels and repression of target
genes related to cell cycle progression, proliferation, apoptosis,
autophagy, senescence, and inflammation (29–31). As a result,
further studies have associated dysregulation of EZH2 with
various diseases, including CVD (cardiac hypertrophy, fibrosis,
atherosclerosis, ischemic heart disease, myocardial regeneration,
cardiomyopathy, pulmonary arterial hypertension, atrial
fibrillation) (26, 32–37), various solid cancers (lung, breast,
endometrial, ovarian, nasopharyngeal, thyroid, liver, prostate,
and glioblastoma) (8, 17, 38–40), as well as hematopoietic cancers
(Non-Hodgkin’s, large B-cell, and follicular lymphoma) (41, 42).
Preclinical studies investigating inhibition of EZH2, primarily
with inhibitors GSK126 and EPZ6437 (Tazemetostat), have been
promising in both CVD and cancer (30, 39, 43–47) and have led
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FIGURE 4 | Supplementation with VDR agonist paricalcitol inhibits sEVs-induced oxidative stress and inflammation in AC16. (A) Oxidative stress levels were
measured using CellROXTM Green Reagent in untreated cells and AC16 cells pretreated for 24 h with ExoL-10 or ExoR+3 from Astronaut D14 and paricalcitol (10 nM)
after 24 h, n = 4. Cells were visualized by fluorescence microscopy and quantified using a fluorescent spectrophotometer. Scale bars, 50 µm. (B) Transcript levels of
inflammation markers (TNF-α, IL-6, IL-1 α, and IL-1β) were measured by qPCR in AC16 pretreated for 24 h with ExoL-10 and ExoR+3 isolated from Astronaut D14
alone or with paricalcitol (10 nM) after 24 h, n = 3. Statistical significance was determined by one-way ANOVA followed by Tukey post-test. *P < 0.05, **P < 0.01, ***P
< 0.001, ns, not significant.

preclinical studies in rodents and observational clinical reports
suggests that vitamin D deficiency or defective VDR is associated
with adverse cardiovascular outcomes (52). Furthermore, low
vitamin D responsiveness is described as a major risk factor for
hypertension, myocardial infarction, heart failure, peripheral
arterial disease, and strokes (53). VDR-null mice exhibit
dysregulation of the renin-angiotensin system (RAS), resulting
in high blood pressure, cardiac hypertrophy, and overall elevated
heart weight-to-body weight ratio (54). Further studies aimed
at elucidating the pathophysiologic mechanisms underlying
the role of vitamin D hormone 1α,25-dihydroxy vitamin D3
(1,25(OH)2D3) showed VDR-deficient mice exhibited lower
bioavailability of nitric oxide (NO) due to reduced endothelial
NO synthase expression, resulting in increased endothelial
dysfunction, arterial stiffness, aortic impedance and remodeling,
and overall impaired systolic and diastolic heart function which
was independent of the alterations in (RAS) (55). Chronic
supplementation of 1,25(OH)2D3 has been shown to modulate
vascular tone and lower blood pressure by reducing reactive
oxygen species production and decreasing cyclooxygenase-1

Frontiers in Cardiovascular Medicine | www.frontiersin.org

(COX-1) mRNA and protein expression in spontaneously
hypertensive rats (56). Several preclinical studies have aimed
to address the translational implications of these findings.
Two prospective cohort studies, one in 613 men and 1,198
women (healthcare professionals) without baseline hypertension
and the other in 38,388 men and 77,532 women, suggested
lower 1,25(OH)2D3 levels were associated with increased risk
of hypertension independent of other covariates, including
age, BMI, physical activity, race, and menopause status (57).
Similarly, a meta-analysis conducted by Kunutsor et al. on
283,587 participants revealed that the top third of participants
with the highest 1,25(OH)2D3 levels had a 30% reduced risk
of developing hypertension (58). Although the association
between 25(OD)D levels and risks of CVD is well-accepted, the
therapeutic benefits of vitamin D supplementation remain largely
unclear. Currently, there is an ongoing randomized clinical trial
investigating the association between dietary vitamin D3 and
omega-3-fatty acids (VITAL, NCT01169259) incidence of CVD
or cancer. Principle results of VITAL show a significant reduction
in cancer mortality in patients taking vitamin D supplements, but
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no effect was observed regarding an incidence of CVD endpoints
(59). In line with these studies, recent evidence suggests that
women with low vitamin D levels are at higher risk of breast
cancer. Radiotherapy is commonly used in patients with breast
cancer to reduce tumor size before surgery and tumor recurrence
after surgery. However, recent studies suggest that radiotherapy
also affects vitamin D metabolism and distribution in the body,
which may ultimately counteract radiotherapy outcomes. Taken
together, further studies are required to validate and elucidate
the role of VDR deficiency in the context of CVD and cancer
risks, especially when modified by covariates associated with
spaceflight, such as radiation.
While we did observe the restoration of VDR expression
following EZH2 inhibition with GSK126 as well as antiinflammatory and anti-oxidant effects of paricalcitol
supplementation in AC16 human cardiomyocyte cell line
treated with astronaut-derived exosomes, further studies using
a larger sample size and paired clinical data are warranted to
validate these findings. Further longitudinal prospective studies
using astronaut blood samples and paired clinical data are
needed to validate whether circulating 1,25(OH)2D3 levels
in astronauts are altered before, during, and after spaceflight
and whether there would be a net benefit from vitamin D
supplementation in reducing space flight associated health risks.
Overall, our study provides a promising avenue to investigate
vitamin D supplementation or EZH2 inhibitors as a method for
mitigating spaceflight-associated chronic adverse health risks.
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